Not yet recruiting
Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients
NCT07941479· Phase 2· Sinfatin S.L· Source
Not yet recruiting
Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
NCT07913763· Phase 2· Sinfatin S.L· Source
Recruiting
Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.
2023-507870-42-00· Phase 2· Sinfatin S.L.· Source
Recruiting
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
2025-524308-31-00· Phase 2· Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.· Source
Not yet recruiting
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· Phase 2· Fundacion PETHEMA· Source
Recruiting
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
NCT07583446· Phase 2/3· Seismic Pharmaceuticals Operations LLC· Source
Not yet recruiting
A study that compares Depigoid Olea (a medication to treat olive pollen allergies) and placebo in patients who have a runny nose and pink and itchy eyes due to olive pollen allergy.
2026-525840-13-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy
2025-523238-17-00· Phase 2· Fundacion PETHEMA· Source
Recruiting
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547· Phase 2· Fundación GECP· Source
Recruiting
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Source
Contact: Jesús Lorenzo Algarra, Dr (principal investigator)
Active, not recruiting
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· Phase 2· Hoffmann-La Roche· Source
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· Phase 3· Kura Oncology, Inc.· Source
Not yet recruiting
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
NCT07082452· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION)
2024-519521-37-01· Phase 2/3· Corxel Pharmaceuticals Co. Ltd.· Source
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244· Phase 3· Pharmazz, Inc.· Source
Recruiting
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· Phase 2· Intra-Cellular Therapies Inc.· Source
Recruiting
Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
NCT06863155· Fundación EPIC· Source
Contact: Juan Gabriel Córdoba Soriano, MD, PhD
Recruiting
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837· Phase 3· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Active, not recruiting
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source
Recruiting
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism
2024-511959-18-01· Phase 3· Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Active, not recruiting
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT06321757· Fundación EPIC· Source
Recruiting
A Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia
2022-502741-10-00· Phase 1/2· Sumitomo Pharma America Inc.· Source
Recruiting
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Almudena Layos-Romero
Active, not recruiting
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
NCT05599061· Fundación EPIC· Source
Recruiting
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
NCT05558319· Phase 3· PETHEMA Foundation· Source
Contact: Irene Gómez Catalán
Active, not recruiting
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source
Contact: Jesus Lorenzo Algarra, MD
Recruiting
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
NCT05283356· Phase 4· Fundacin Biomedica Galicia Sur· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progression in Huntington's disease patients.
2024-518875-73-00· Phase 3· IIS La Fe· Source
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Active, not recruiting
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
NCT04604197· Fundación EPIC· Source
Active, not recruiting
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
NCT03767621· Fundación EPIC· Source
Active, not recruiting
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 years old, in good general health and newly diagnosed multiple myeloma.
2024-516905-22-00· Phase 3· Fundacion PETHEMA· Source
Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245· Manuel Monreal· Source
Contact: María Melero